Literature DB >> 22740798

Low Bone Mineral Density in Middle-Aged Breast Cancer Survivors: Prevalence and Associated Factors.

Délio Marques Conde1, Lúcia Costa-Paiva, Edson Zangiacomi Martinez, Aarão Mendes Pinto-Neto.   

Abstract

BACKGROUND: The aim of this study was to investigate the prevalence of low bone mineral density (BMD) and associated factors in middle-aged breast cancer survivors (BCS). PATIENTS AND METHODS: A cross-sectional study was conducted with 70 BCS of 45-65 years of age undergoing complete oncology treatment. Logistic regression models were used to identify factors associated with low BMD (osteopenia and osteoporosis taken together as a single group).
RESULTS: The mean age of participants was 53.2 ± 5.9 years. BMD was low at the femoral neck in 28.6% of patients and at the lumbar spine in 45.7%. Body mass index ≤ 30 kg/m(2) (adjusted odds ratio (OR) 3.43; 95% confidence interval (CI) 1.0-11.3) and postmenopausal status (OR adjusted 20.42; 95% CI 2.0-201.2) were associated with low BMD at the lumbar spine. Femoral neck measurements, age > 50 years (OR 3.41; 95% CI 1.0-11.6), and time since diagnosis > 50 months (OR adjusted 3.34; 95% CI 1.0-11.3) increased the likelihood of low BMD.
CONCLUSION: These findings show that low BMD is common in middle-aged BCS. Factors were identified that may affect BMD in BCS and should be considered when implementing strategies to minimize bone loss in middle-aged women with breast cancer.

Entities:  

Year:  2012        PMID: 22740798      PMCID: PMC3376365          DOI: 10.1159/000337763

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  24 in total

1.  Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001.

Authors:  M R Soules; S Sherman; E Parrott; R Rebar; N Santoro; W Utian; N Woods
Journal:  Menopause       Date:  2001 Nov-Dec       Impact factor: 2.953

Review 2.  Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature.

Authors:  E J Waugh; M-A Lam; G A Hawker; J McGowan; A Papaioannou; A M Cheung; A B Hodsman; W D Leslie; K Siminoski; S A Jamal
Journal:  Osteoporos Int       Date:  2008-06-04       Impact factor: 4.507

3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Authors:  J A Kanis
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

4.  Quality of life in Brazilian breast cancer survivors age 45-65 years: associated factors.

Authors:  Délio Marques Conde; Aarão Mendes Pinto-Neto; César Cabello; Danielle Santos-Sá; Lúcia Costa-Paiva; Edson Zangiacomi Martinez
Journal:  Breast J       Date:  2005 Nov-Dec       Impact factor: 2.431

5.  Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause.

Authors:  MaryFran R Sowers; Huiyong Zheng; Mary L Jannausch; Daniel McConnell; Bin Nan; Sioban Harlow; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2010-03-09       Impact factor: 5.958

6.  Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.

Authors:  L Vehmanen; T Saarto; I Elomaa; P Mäkelä; M Välimäki; C Blomqvist
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

7.  Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

Authors:  Zhao Chen; Michael Maricic; Tamsen L Bassford; Mary Pettinger; Cheryl Ritenbaugh; Ana Maria Lopez; David H Barad; Margery Gass; Meryl S Leboff
Journal:  Arch Intern Med       Date:  2005-03-14

8.  Bone Health and Falls: Fracture Risk in Breast Cancer Survivors With Chemotherapy-Induced Amenorrhea.

Authors:  Kerri M Winters-Stone; Lillian Nail; Jill A Bennett; Anna Schwartz
Journal:  Oncol Nurs Forum       Date:  2009-05-01       Impact factor: 2.172

9.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

10.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.

Authors:  P F Bruning; M J Pit; M de Jong-Bakker; A van den Ende; A Hart; A van Enk
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

View more
  5 in total

1.  Bone Metastasis in Breast Cancer.

Authors:  Ingo J Diel
Journal:  Breast Care (Basel)       Date:  2012-04-24       Impact factor: 2.860

2.  Mind the gaps: missed opportunities to promote bone health among cancer survivors.

Authors:  Hawley C Almstedt; Heather P Tarleton
Journal:  Support Care Cancer       Date:  2014-11-05       Impact factor: 3.603

3.  Soy isoflavone intake and bone mineral density in breast cancer survivors.

Authors:  Michelle L Baglia; Kai Gu; Xianglan Zhang; Ying Zheng; Peng Peng; Hui Cai; Ping-Ping Bao; Wei Zheng; Wei Lu; Xiao-Ou Shu
Journal:  Cancer Causes Control       Date:  2015-02-17       Impact factor: 2.506

4.  Combined aerobic and resistance training improves bone health of female cancer survivors.

Authors:  Hawley C Almstedt; Silvie Grote; Joshua R Korte; Stephanie Perez Beaudion; Todd C Shoepe; Sarah Strand; Heather P Tarleton
Journal:  Bone Rep       Date:  2016-09-21

5.  High Bone Mineral Density of the Lumbar Spine Is Positively Associated with Breast Cancer.

Authors:  Larissa Vaz Gonçalves; Karine Anusca Martins; Jordana Carolina Marques Godinho-Mota; Raquel Machado Schincaglia; Ana Luisa Lima Sousa; Ruffo Freitas-Junior
Journal:  Biomed Res Int       Date:  2019-05-23       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.